Dual-Target EBV PCR Assay for Reliable Quantitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a reliable, sensitive, and reproducible method for detecting and quantifying Epstein Barr Virus (EBV) in samples, particularly for managing transplant recipients and diagnosing EBV-associated diseases, given the virus's widespread prevalence and frequent recombination, which existing methods struggle to address effectively.
Innovation Solution
A dual-target real-time PCR assay using novel primers and probes designed to target conserved regions of the EBV genome, specifically the IR-1 repeat, LMP2A, EBNA-1, BMRF-2, and Reductase/BORF-2, to ensure inclusivity and prevent cross-reactivity with other herpesviruses, allowing for sensitive and specific detection and quantitation of EBV nucleic acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional PCR methods are used for EBV detection, then the detection process is simple, but the sensitivity and specificity are insufficient to reliably detect EBV amidst widespread prevalence and frequent recombination
Solution Approach 1:
The patent divides the EBV detection into multiple independent target regions (IR-1 repeat, LMP2A, EBNA-1, BMRF-2, Reductase/BORF-2) and designs separate primer-probe sets for each. This segmentation allows the assay to detect EBV through multiple independent pathways, improving reliability by ensuring that recombination or mutation in one region does not prevent detection, while maintaining manageable complexity through modular assay design
Solution Approach 2:
The patent creates a multi-functional assay system that can detect multiple EBV target regions simultaneously using a single real-time PCR platform. The dual-target design with multiple primer-probe sets enables the assay to function as both a sensitive detection tool and a quantification method, while the standardized protocol maintains ease of operation across different clinical laboratory settings
2Measurement precision
If existing detection methods are used, then the操作流程 is straightforward, but the sensitivity and specificity are insufficient for accurate EBV detection and quantification
Solution Approach 1:
The patent introduces fluorescently labeled probes as intermediaries between the target EBV DNA and the detection system. These probes hybridize specifically to the amplified DNA sequences and emit fluorescent signals that can be precisely quantified in real-time. This intermediary mechanism enables highly precise detection and quantification of EBV nucleic acids while the automated real-time PCR process maintains operational simplicity by eliminating the need for post-amplification processing steps
Solution Approach 2:
The patent replaces traditional mechanical detection methods (such as gel electrophoresis and visual analysis) with optical detection using fluorescent probes and real-time measurement systems. This substitution enables precise quantification of EBV DNA through fluorescent signal intensity while maintaining ease of operation through automated data collection and analysis, eliminating manual intervention steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay provides rapid, accurate, and reproducible detection and quantitation of EBV, enhancing clinical management and diagnosis by improving sensitivity and specificity compared to traditional methods, suitable for use in clinical laboratories and blood screening.
Implementation Method 1
a first set of primers and a first probe specific for a first target nucleic acid of EBV; and a second set of primers and a second probe specific for a second target nucleic acid of EBV
Implementation Method 2
performing the polymerase chain reaction (PCR) amplification and detection of EBV in a single test tube or vessel
Data Source
AI summary
Methods for the rapid detection of the presence or absence of Epstein Barr Virus (EBV) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting EBV, and kits are provided that are designed for the detection of target regions of EBV. Also described are kits, reaction mixtures, and oligonucleotides (e.g., primer and probe) for the amplification and detection of EBV. Also described are primers and probes that detect different regions of EBV, and can be employed in a dual target assay for simultaneously detecting two different and non-overlapping target regions of EBV.